Drug Allergy

Patients with stroke and inaccurate NSAID allergy labels had poorer outcomes including major adverse cardiovascular events, peripheral vascular disease and death, according to a study published in Stroke.

SAN ANTONIO — With a little patience, physicians can challenge and delabel NSAID hypersensitivity in the office, David A. Khan, MD, said during the 16th Annual Allergy, Asthma & Immunology CME Conference.

As asthma and allergy continue to affect more people, the importance of advanced practitioners in enhancing patient safety, addressing health care disparities and increasing treatment access has come to the forefront of patient care.

Hypersensitivity to polyethylene glycol may be rare, but when reactions to PEG in drugs do occur, they often are due to molecular weights of 3350 and higher, according to a study published in Annals of Allergy, Asthma & Immunology.

WASHINGTON — When children have anaphylaxis with breathing difficulties, drug reactions and epinephrine doses, pediatric ICU admission is likely, according to a poster presentation here.

Although 11.3% of households surveyed reported drug hypersensitivities, the prevalence of different hypersensitivities varied significantly, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

At the American College of Allergy, Asthma & Immunology Annual Scientific Meeting, Jay A. Lieberman, MD, FACAAI, discussed upcoming changes to anaphylaxis guidelines and treatment strategies, including new epinephrine delivery methods.

ANAHEIM, Calif. — Utilizing technology and patient education are strategies that can maintain a drug allergy de-label, Allison C. Ramsey, MD, FACAAI, said at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

ANAHEIM, Calif. — Patients with insulin allergy were treated successfully with omalizumab, rituximab and/or mycophenolate, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Dupilumab may be a safe and effective therapy for patients with drug reactions with eosinophilia and systemic symptoms, or DRESS, according to a case series published in The Journal of Allergy and Clinical Immunology: In Practice.